Additional European Equity News - 1st September 2026

A wrap of this kind is a morning digest rather than a single catalyst; the tradable content concentrates in the items where guidance moved, not where numbers merely printed.

Newsquawk StaffPublished 1 Sept 2026, 07:01On the live feed at 06:41 — 7 more headlines followed before this page went public

Newsquawk headlines

14:00

Newsquawk European Market Wrap - 1st September 2026

07:10

EUROPEAN OPEN: Activist Elliott builds stake in AI FP; RKT LN wins first federal NEC bellwether trial; ALC SW joins US most-favoured nation drug pricing deal; NOVN SW pauses eight trials after three fatalities; BNZL LN raises operating profit guidance

06:41

Additional European Equity News - 1st September 2026

06:42

European Equity pre-Market Summary - 1st September 2026: Strong results from Bunzl; Air Liquide draws interest

06:46

[MARKET ANALYSIS] Japanese 10yr yield eclipses 3%, lifting global peers; focus on Bessent pushing for a September BoJ hike & fiscal concerns

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

Aedifica (AED BB) - H1 2026 (EUR): Rental Income 292.3mln, +62% Y/Y; EPRA EPS 2.71, +5% Y/Y. Guides FY26 EPRA EPS at 5.35 and says that expected synergies will accelerate further, reaching a full run-rate impact of at least EUR 16mln during 2027. (Aedifica)

AstraZeneca (AZN LN) - Co. announces that its Tagrisso plus Orpathys demonstrated statistically significant and highly clinically meaningful improvement in progression-free survival in 1st-line MET-overexpressing EGFR-mutated lung cancer. Additionally, the Co. announces that they have acquired worldwide rights to develop and commercialise Zegfrovy. Furthermore, the Co. says Enhertu has been approved in the EU for 1L HER2-positive metastatic breast cancer, based on the Destiny-Breast09 phase III trial. (AstraZeneca)

Bavarian Nordic (BAVA DC) - Co. launches the first tranche of its DKK 750mln share buyback programme. The first tranche will result in DKK 250mln of share buybacks. (Bavarian Nordic)

Bunzl (BNZL LN) - H1 2026 (GBP): Revenue 5.93bln (prev. 5.76bln Y/Y), Adj. Operating Profit 440.6mln (prev. 404.5mln Y/Y), Adj. EPS 0.877 (prev. 0.778 Y/Y). Raises its FY26 guidance, now sees operating margin to be broadly flat Y/Y (prev. guided slightly down Y/Y). Announces a new GBP 500mln share buyback programme. (Bunzl)

DHL Group (DHL GY) - Co. says its Global Forwarding unit has acquired Uruguay's Aero Cargas; no terms disclosed. Elsewhere, the Co. announces that it has completed its corporate reorganisation. Under the reorganisation, Germany's Mail and Parcel business will continue to operate under Deutsche Post. (T21/DHL)

GSK (GSK LN) - Co. announces positive phase II data for its mRNA seasonal influenza vaccine candidate and intends to start a phase III efficacy trial in September 2026. (GSK)

London Stock Exchange (LSEG LN) - Co. announces plans to launch UK tokenised equity structures and forms a partnership with Payward. (LSEG)

UK Housing - Nationwide Housing Prices (Aug YY) 1.6% vs. Exp. 2.1% (Prev. 1.4%); MM 0.2% vs. Exp. 0.1% (Prev. -0.1%). (Nationwide)

Veolia (VIE FP) - Co. signs 3 strategic MoUs with companies in Saudi Arabia in water technologies and hazardous waste management. (Veolia)

Vodafone (VOD LN) - Co. announces that OXG, its fibre JV in Germany, will have a new shareholder. (Vodafone)

Accor (AC FP) reinitiated with Buy at Deutsche Bank

Context

Bunzl is the clearest case: a distribution business raising margin guidance and attaching a fresh buyback has historically been received better than the headline growth rate alone would imply, because the peer set trades on margin trajectory and capital return rather than top-line beats. The pharma cluster (AstraZeneca's lung cancer readout and EU breast cancer approval, GSK's mRNA flu phase II) fits the established pattern in large-cap pharma where pipeline news moves the single name on peak-sales assumptions but rarely the sector, with the follow-on being sell-side model updates rather than an immediate re-rating. Buyback announcements (Bavarian Nordic, Bunzl) tend to provide only transient support unless they signal a shift in capital allocation policy. The Nationwide miss on the annual rate is the lone macro input, and UK house price prints of this size have historically mattered mainly for the housebuilders and domestically focused banks rather than sterling. The LSEG tokenised equity announcement is strategic rather than earnings-relevant; prior exchange-group forays into digital asset infrastructure have moved the stock little on the day. The Vodafone German fibre JV shareholder change is worth monitoring for deleveraging implications, as infrastructure stake sales have been the group's recurring lever.

Related headlines

© 2026 Newsquawk. All rights reserved.